• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    ASP Isotopes Inc. Completes Commissioning of First Quantum Enrichment Laser System and Starts Production of Commercial Samples of Ytterbium-176

    4/1/25 8:17:18 AM ET
    $ASPI
    Major Chemicals
    Industrials
    Get the next $ASPI alert in real time by email

    - Ytterbium-176 is a critical material used in the production of radioisotopes for oncology treatments, including Novartis' Pluvicto.

    - The Company expects to be able to achieve a 99.75% enrichment for Ytterbium-176 and offer highly enriched Ytterbium-176 for commercial sale during 2025.

    - The Company anticipates now being able to proceed with the plans to construct Nickel-64, Gadolinium-160 and Lithium-6/7 Quantum Enrichment facilities.

    - The Company intends to continue its discussions with nuclear regulatory authorities for the authorization to construct HALEU uranium enrichment facilities using Quantum Enrichment in South Africa and other countries.

    WASHINGTON, April 01, 2025 (GLOBE NEWSWIRE) -- ASP Isotopes Inc. NASDAQ: ASPI ("ASP Isotopes" or the "Company"), an advanced materials company dedicated to the development of technology and processes for the production of isotopes for use in multiple industries, today announced that it has started the production of commercial samples of highly enriched Ytterbium-176, following the successful commissioning of the laser system at its first Quantum Enrichment facility in Pretoria, South Africa.

    This is the Company's third enrichment facility in South Africa and its first isotope enrichment facility to utilize Quantum Enrichment, a novel laser-based method of enrichment. The Company believes that this proprietary technology is not only more efficient and scalable than other enrichment technologies but also has considerable advantages with respect to capital efficiency and industrial pollution.

    After a construction phase which lasted just 8 months, versus an anticipated timeline of 18 months, the commissioning phase took 6 months, versus an anticipated timeline of 3-6 months. The Company's scientists overcame a number of unexpected challenges, including faults with OEM supplied time-of-flight mass spectrometers and vacuum pumps. The Company's scientists continue to optimize various steps of the process but have overcome the major problems inherent in any new process and are successfully enriching Ytterbium-176 that will be suitable for commercial supply. The Company expects to be able to achieve a 99.75% enrichment for Ytterbium-176 and offer highly enriched Ytterbium-176 for commercial sale during 2025.

    "The success of this project is testament to the strong working relationship between our in-house scientists and technicians and the world class scientists in the fields of nuclear physics and laser technology that we are working with from our universities of Stellenbosch and Witwatersrand in South Africa," said Hendrik Strydom, ASP Isotopes Inc.'s Chief Technology Officer.

    Ytterbium-176 (176Yb) is a key stable isotope used in the production of Lutetium-177 (177Lu). Lutetium-177 is an emerging beta emitting radiopharmaceutical used in oncology drugs, such as Novartis' Pluvicto. There are currently two FDA approved drugs and numerous ongoing clinical trials for drugs that require Lutetium-177.

    Consensus forecasts for Novartis' Pluvicto exceed $4 billion and the beta emitting radiopharmaceutical market is expected to exceed $15 billion per annum in the next decade.(1) The supply chain for this radioisotope has been particularly challenged with recent industry reports highlighting over two months treatment delay due to lack of drug availability.(2) The Company believes that it will be one of the only suppliers of commercial quantities of Ytterbium-176 and other similar isotopes in the Western world.

    "Currently, there exist significant supply-side challenges for many essential radioisotopes used in various oncology treatments. We have received a considerable amount of interest from customers in North America, Europe and Asia for Ytterbium-176 and we look forward to easing supply chains and improving the quality of life for thousands of patients every year," said Paul Mann, ASP Isotopes Inc.'s Executive Chairman and CEO.

    Additional Planned Quantum Enrichment Plants – Nickel-64, Gadolinium-160 and Lithium-6/7

    Based on the results of the commissioning phase of the Ytterbium-176 enrichment facility, the Company is now accelerating plans to construct Nickel-64 and Lithium-6/7 enrichment facilities in South Africa. The Company believes that there is an urgent need for all three isotopes from Western-based producers.

    Nickel-64 is currently used to produce Copper-64, in a cyclotron, and based on discussions with potential customers, has significant supply-side challenges. Copper-64 is a positron and beta emitting isotope of copper, with applications for molecular radiotherapy and positron emission tomography.

    Lithium-7 is currently used as an alkalizing agent for the coolant in Pressure Water Reactors (PWRs) and it is predicted that Lithium-7 will be used as part of the molten lithium fluoride in molten-salt reactors which are expected to become used in the nuclear energy industry next decade. Western supplies of Lithium-7 are currently provided by Russia.

    It is widely anticipated that Lithium-6 will be required to enable nuclear fusion power plants, which are currently in development. It is widely anticipated that nuclear fusion will be one of the cleanest forms of energy, with potential for low carbon baseload energy with no long-lived radionuclide waste. There is currently no producer of Lithium-6 in commercial quantities, yet most power plant designs need tonnage of Lithium-6 for operations. With 93% of private fusion companies aiming to deliver a fusion prototype device during the 2030s, according to the Fusion Industry Association, this represents a key emerging supply chain for fusion nuclear power.

    Quantum Enrichment – A Novel Enrichment Technique Potentially Capable of Efficiently Producing Advanced Nuclear Fuels

    The Company believes its Quantum Enrichment process will potentially also be able to produce HALEU (High Assay Low Enriched Uranium) at an attractive price, allowing new nuclear energy to become available at a "green discount" to carbon-intensive electricity production processes. This "green energy cost advantage" is expected to help accelerate the global adoption of new nuclear energy, with a corresponding benefit to climate goals.

    HALEU will be required for use in the next generation of advanced nuclear reactors, such as SMRs (small modular reactors), that are now under development for commercial and government uses. Currently, there are no Western producers of HALEU in commercial quantities, and many SMR companies worldwide face substantial delays until this fuel supply issue is resolved. The Nuclear Energy Institute estimates that there may be a HALEU supply shortage of approximately 3,000 metric tons by 2035(3). However, based on discussions with and the interest received from potential customers, the Company believes this figure may be significantly larger.

    The Company is in discussions with potential customers that anticipate requiring High Assay Low Enriched Uranium (HALEU), valued at over $37 billion(4) at recent market prices. The Company previously announced that it has entered into MOUs (Memorandum of Understanding) and term-sheets with two US-based SMR companies including TerraPower LLC, for HALEU supply that contemplate the SMR companies making capital investments into the development of HALEU facilities. The Company intends to continue its discussions with nuclear regulatory authorities in multiple countries, including South Africa, the United Kingdom and the United States, regarding the potential construction of a Quantum Enrichment facility for uranium enrichment.

    (1)Lutetium-177 (Lu-177) Market Size, Scope And Forecast Report (marketresearchintellect.com)
    (2)Ravi et al, Clinical Implementation of 177Lu-PSMA-617 in the United States: Lessons Learned and Ongoing Challenges; J Nuc Med March 2023, 64 (3) 349-350
    (3)UK releases roadmap to quadruple nuclear energy capacity: Nuclear Policies - World Nuclear News (world-nuclear-news.org)
    (4)NEI-Letter-for-Secretary-Granholm_HALEU-2021.pdf
      

    About ASP Isotopes Inc.

    ASP Isotopes Inc. is a development stage advanced materials company dedicated to the development of technology and processes to produce isotopes for use in multiple industries. The Company employs proprietary technology, the Aerodynamic Separation Process ("ASP technology"). The Company's initial focus is on producing and commercializing highly enriched isotopes for the healthcare and technology industries. The Company also plans to enrich isotopes for the nuclear energy sector using Quantum Enrichment technology that the Company is developing. The Company has isotope enrichment facilities in Pretoria, South Africa, dedicated to the enrichment of isotopes of elements with a low atomic mass (light isotopes).

    There is a growing demand for isotopes such as Silicon-28, which will enable quantum computing, and Molybdenum-100, Molybdenum-98, Zinc-68, Ytterbium-176, and Nickel-64 for new, emerging healthcare applications, as well as Chlorine-37, Lithium-6, and Uranium-235 for green energy applications. The ASP Technology (Aerodynamic Separation Process) is ideal for enriching low and heavy atomic mass molecules. For more information, please visit www.aspisotopes.com.

    Forward Looking Statements

    This press release contains "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations, and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy, and other future conditions. Forward-looking statements can be identified by words such as "believes," "plans," "anticipates," "expects," "estimates," "projects," "will," "may," "might," and words of a similar nature. Examples of forward-looking statements include, among others but are not limited to, statements relating to the commencement of supply of isotopes to customers and the application of new technology for the enrichment of isotopes, the planned construction of additional isotope enrichment facilities, the future of the company's enrichment technologies as applied to uranium enrichment, the outcome of the company's initiative to commence enrichment of uranium in South Africa and the company's discussions with nuclear regulators, and statements we make regarding expected operating results, such as future revenues and prospects from the potential commercialization of isotopes, future performance under contracts, and our strategies for product development, engaging with potential customers, market position, and financial results. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict, many of which are outside our control. Our actual results, financial condition, and events may differ materially from those indicated in the forward-looking statements based upon a number of factors. Forward-looking statements are not a guarantee of future performance or developments. You are strongly cautioned that reliance on any forward-looking statements involves known and unknown risks and uncertainties. Therefore, you should not rely on any of these forward-looking statements. There are many important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements, including our reliance on the efforts of third parties; our ability to complete the construction and commissioning of our enrichment plants or to commercialize isotopes using the ASP technology or the Quantum Enrichment Process; our ability to obtain regulatory approvals for the production and distribution of isotopes; the financial terms of any current and future commercial arrangements; our ability to complete certain transactions and realize anticipated benefits from acquisitions and contracts; dependence on our Intellectual Property (IP) rights, certain IP rights of third parties; the competitive nature of our industry; and the factors disclosed in Part I, Item 1A. "Risk Factors" of the company's Annual Report on Form 10-K for the fiscal year ended December 31, 2024 and any amendments thereto and in the company's subsequent reports and filings with the U.S. Securities and Exchange Commission. Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise. No information in this press release should be interpreted as an indication of future success, revenues, results of operation, or stock price. All forward-looking statements herein are qualified by reference to the cautionary statements set forth herein and should not be relied upon.

    Contacts

    Jason Assad – Investor relations

    Email: [email protected]

    Telephone: 561-709-3043



    Primary Logo

    Get the next $ASPI alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ASPI

    DatePrice TargetRatingAnalyst
    10/4/2024$4.50Buy
    Canaccord Genuity
    12/5/2023$3.25Buy
    H.C. Wainwright
    More analyst ratings

    $ASPI
    SEC Filings

    See more
    • SEC Form S-3 filed by ASP Isotopes Inc.

      S-3 - ASP Isotopes Inc. (0001921865) (Filer)

      4/30/25 4:50:02 PM ET
      $ASPI
      Major Chemicals
      Industrials
    • Amendment: SEC Form 10-K/A filed by ASP Isotopes Inc.

      10-K/A - ASP Isotopes Inc. (0001921865) (Filer)

      4/30/25 4:15:05 PM ET
      $ASPI
      Major Chemicals
      Industrials
    • SEC Form 144 filed by ASP Isotopes Inc.

      144 - ASP Isotopes Inc. (0001921865) (Subject)

      4/15/25 8:47:03 AM ET
      $ASPI
      Major Chemicals
      Industrials

    $ASPI
    Leadership Updates

    Live Leadership Updates

    See more
    • ASP Isotopes Inc. Enhances Executive Leadership Team with the Appointment of Heather Kiessling as Chief Financial Officer

      WASHINGTON, June 13, 2024 (GLOBE NEWSWIRE) -- ASP Isotopes Inc. NASDAQ: ASPI ("ASP Isotopes" or the "Company"), an advanced materials company dedicated to the development of technology and processes for the production of isotopes for use in multiple industries, today announced the appointment of Heather Kiessling as its chief financial officer (CFO), effective as of July 1, 2024 (or such earlier date as may be mutually agreed), to support the Company's next pivotal phase of growth. Robert Ainscow, who currently serves as the Company's CFO and chief operating officer (COO), will continue to serve as the Company's COO, enabling him to focus his full time and attention on the Company's operat

      6/13/24 10:56:52 AM ET
      $ASPI
      Major Chemicals
      Industrials
    • Professor Mike Gorley From UK Atomic Energy Authority to Join Board of Directors of ASP Isotopes Inc.

      WASHINGTON, Oct. 19, 2023 (GLOBE NEWSWIRE) -- ASP Isotopes Inc. (NASDAQ:ASPI) ("ASPI", the "Company", "us", "we" or "our"), an advanced materials company dedicated to the development of technology and processes designed to produce isotopes for use in multiple industries, today announced that Professor Mike Gorley, Chief Technologist at the UK Atomic Energy Authority is to join the board of directors of the Company. Professor Gorley is Chief Technologist at the UK Atomic Energy Authority and a visiting Professor at the University of Bristol, U.K. He is a well-known expert in fusion technology and fusion materials. In 2014, Mike was awarded a Ph.D. (DPhil) in Materials Science from Oxford

      10/19/23 8:00:00 AM ET
      $ASPI
      Major Chemicals
      Industrials

    $ASPI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Operating Officer Ainscow Robert bought 19,992 shares, increasing direct ownership by 2% to 919,992 units (SEC Form 4)

      4 - ASP Isotopes Inc. (0001921865) (Issuer)

      7/15/24 10:33:49 AM ET
      $ASPI
      Major Chemicals
      Industrials
    • Chief Executive Officer Mann Paul Elliot bought 39,984 shares, increasing direct ownership by 0.69% to 5,845,627 units (SEC Form 4)

      4 - ASP Isotopes Inc. (0001921865) (Issuer)

      7/15/24 10:33:33 AM ET
      $ASPI
      Major Chemicals
      Industrials
    • Large owner Ak Jensen Investment Management Ltd bought $515,088 worth of shares (161,849 units at $3.18) (SEC Form 4)

      4 - ASP Isotopes Inc. (0001921865) (Issuer)

      7/10/24 5:59:47 PM ET
      $ASPI
      Major Chemicals
      Industrials

    $ASPI
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • ASP Isotopes Inc. Announces Proposed Secondary Listing on the Johannesburg Stock Exchange

      WASHINGTON , April 24, 2025 (GLOBE NEWSWIRE) -- ASP Isotopes Inc. NASDAQ: ASPI ("ASP Isotopes" or the "Company"), an advanced materials company dedicated to the development of technology and processes for the production of isotopes for use in multiple industries, is pleased to announce the proposed secondary listing of the Company's common stock by way of introduction on the Main Board of the Johannesburg Stock Exchange ("JSE").   The Company's common stock will continue to be listed and traded on the Nasdaq Capital Market. ASPI's history and technology is firmly rooted in South Africa and has been developed over four years by the Company's highly skilled South African team members. Furth

      4/24/25 8:00:00 AM ET
      $ASPI
      Major Chemicals
      Industrials
    • ASP Isotopes Inc. Announces Changes in Boards of ASP Isotopes Inc. and Quantum Leap Energy LLC

      - Highly respected South African Businessman, Mr Sipho Maseko, former CEO of Telkom SA Soc Ltd and MD of Vodacom SA, Has Joined the Board of Directors of ASP Isotopes Inc. - Dr. Hendrik Strydom, PhD, Chief Technology Officer of ASP Isotopes Inc., is transitioning from the Board of Directors of ASP Isotopes Inc. to the Board of Managers of Quantum Leap Energy LLC. - The Company Intends to pursue the Separation of its Nuclear Fuels Business, Quantum Leap Energy LLC, and Specialist Isotope Products and Related Services Business in Two Independent Companies during 2H 2025. WASHINGTON, April 15, 2025 (GLOBE NEWSWIRE) -- ASP Isotopes Inc. NASDAQ: ASPI ("ASP Isotopes" or the "Company"),

      4/15/25 8:00:00 AM ET
      $ASPI
      Major Chemicals
      Industrials
    • ASP Isotopes Inc. Completes Commissioning of First Quantum Enrichment Laser System and Starts Production of Commercial Samples of Ytterbium-176

      - Ytterbium-176 is a critical material used in the production of radioisotopes for oncology treatments, including Novartis' Pluvicto. - The Company expects to be able to achieve a 99.75% enrichment for Ytterbium-176 and offer highly enriched Ytterbium-176 for commercial sale during 2025. - The Company anticipates now being able to proceed with the plans to construct Nickel-64, Gadolinium-160 and Lithium-6/7 Quantum Enrichment facilities. - The Company intends to continue its discussions with nuclear regulatory authorities for the authorization to construct HALEU uranium enrichment facilities using Quantum Enrichment in South Africa and other countries. WASHINGTON, April 01, 202

      4/1/25 8:17:18 AM ET
      $ASPI
      Major Chemicals
      Industrials

    $ASPI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Operating Officer Ainscow Robert sold $1,121,347 worth of shares (200,000 units at $5.61), decreasing direct ownership by 12% to 1,419,992 units (SEC Form 4)

      4 - ASP Isotopes Inc. (0001921865) (Issuer)

      4/17/25 7:57:41 PM ET
      $ASPI
      Major Chemicals
      Industrials
    • Chief Executive Officer Mann Paul Elliot sold $5,326,397 worth of shares (950,000 units at $5.61), decreasing direct ownership by 11% to 7,315,454 units (SEC Form 4)

      4 - ASP Isotopes Inc. (0001921865) (Issuer)

      4/17/25 7:57:18 PM ET
      $ASPI
      Major Chemicals
      Industrials
    • Chief Operating Officer Ainscow Robert was granted 400,000 shares, increasing direct ownership by 33% to 1,619,992 units (SEC Form 4)

      4 - ASP Isotopes Inc. (0001921865) (Issuer)

      4/15/25 8:42:42 AM ET
      $ASPI
      Major Chemicals
      Industrials

    $ASPI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Canaccord Genuity initiated coverage on ASP Isotopes with a new price target

      Canaccord Genuity initiated coverage of ASP Isotopes with a rating of Buy and set a new price target of $4.50

      10/4/24 7:13:36 AM ET
      $ASPI
      Major Chemicals
      Industrials
    • H.C. Wainwright initiated coverage on ASP Isotopes with a new price target

      H.C. Wainwright initiated coverage of ASP Isotopes with a rating of Buy and set a new price target of $3.25

      12/5/23 7:36:42 AM ET
      $ASPI
      Major Chemicals
      Industrials

    $ASPI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by ASP Isotopes Inc.

      SC 13G - ASP Isotopes Inc. (0001921865) (Subject)

      11/14/24 3:01:19 PM ET
      $ASPI
      Major Chemicals
      Industrials
    • Amendment: SEC Form SC 13G/A filed by ASP Isotopes Inc.

      SC 13G/A - ASP Isotopes Inc. (0001921865) (Subject)

      11/7/24 4:15:14 PM ET
      $ASPI
      Major Chemicals
      Industrials
    • SEC Form SC 13G filed by ASP Isotopes Inc.

      SC 13G - ASP Isotopes Inc. (0001921865) (Subject)

      11/3/23 4:15:20 PM ET
      $ASPI
      Major Chemicals
      Industrials

    $ASPI
    Financials

    Live finance-specific insights

    See more
    • Mobilicom and ASP Isotopes Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

      ORLANDO, FL / ACCESSWIRE / September 13, 2024 / RedChip Companies will air interviews with Mobilicom Ltd. (NASDAQ:MOB) and ASP Isotopes Inc. (NASDAQ:ASPI) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, September 14, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:Mobilicom: https://www.redchip.com/assets/access/mob_accessASP Isotopes: https://www.redchip.com/assets/access/aspi_accessOren Elkayam, Founder and CEO of Mobilicom, appears on the RedChip Small Stocks, Big Money™ show on Bloomberg TV to provide a corporate update. Mobilicom presents a

      9/13/24 9:00:00 AM ET
      $ASPI
      $BOXL
      $MOB
      Major Chemicals
      Industrials
      Other Consumer Services
      Real Estate
    • ASP Isotopes and Calidi Biotherapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

      ORLANDO, FL / ACCESSWIRE / May 24, 2024 / RedChip Companies will air interviews with ASP Isotopes Inc. (NASDAQ:ASPI) and Calidi Biotherapeutics Inc. (NYSE:CLDI) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, May 25, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:ASP Isotopes: https://www.redchip.com/assets/access/aspi_accessCalidi Biotherapeutics: https://www.redchip.com/assets/access/cldi_accessIn an exclusive interview, Paul Mann, CEO of ASP Isotopes, appears on the RedChip Small Stocks Big Money™ show on Bloomberg TV to provide a corporate u

      5/24/24 9:00:00 AM ET
      $ASPI
      $CLDI
      Major Chemicals
      Industrials
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • INNO Holdings and ASP Isotopes Interviews to Air on the RedChip Small Stocks Big Money(R) Show on Bloomberg TV

      ORLANDO, FL / ACCESSWIRE / January 19, 2024 / RedChip Companies will air interviews with INNO Holdings, Inc. (NASDAQ:INHD) and ASP Isotopes, Inc. (NASDAQ:ASPI) on The RedChip Small Stocks Big Money® Show, a sponsored program on Bloomberg TV, this Saturday, January 20, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:INNO Holdings: https://www.redchip.com/assets/access/inhd_accessASP Isotopes: https://www.redchip.com/assets/access/aspi_accessIn an exclusive interview, Alice Gong, COO of INNO Holdings, appears on the RedChip Small Stocks Big Money® Show on Bloomberg TV to provide a corporate update

      1/19/24 1:10:00 PM ET
      $ASPI
      Major Chemicals
      Industrials